OBJECTIVE: The aim of this study was to determine whether ethnicity impacts graft outcomes in kidney transplant patients converted to sirolimus (SRL) and maintained on either calcineurin inhibitors (CI) or mycophenolate mofetil (MMF) with steroids. METHODS: This study analyzed kidney transplants converted to SRL and transplanted between July 1991 and April 2007. Patients were divided into 4 groups: group 1: African-Americans converted to SRL + CI; group 2: non-African-Americans converted to SRL + CI; group 3: African-Americans converted to SRL + MMF; group 4: non-African-Americans converted to SRL + MMF. RESULTS: A total of 242 patients was included. Demographics, baseline immunosuppression, and reason for SRL conversion were sim...
INTRODUCTION: This study examines the efficacy and toxicity of sirolimus used as primary immunosu...
BACKGROUND: Conversion to sirolimus from calcineurin inhibitor- (CNI), azathioprine- (AZA) and mycop...
BACKGROUND: Replacing a calcineurin inhibitor (CNI) with sirolimus (SRL) may preserve kidney graft f...
OBJECTIVE: The aim of this study was to determine whether ethnicity impacts graft outcomes in kid...
Background/Purpose: Information is needed on renal function improvement after late elimination of ca...
INTRODUCTION: Previous studies have suggested that African-American (AA) ethnicity is a risk fact...
Background. Everolimus (EVR) has demonstrated good efficacy after renal transplantation. Racial disp...
BACKGROUND: Calcineurin-inhibitor (CNI)-induced nephrotoxicity frequently complicates transplantatio...
Copyright © 2012 Bertram L. Kasiske et al. This is an open access article distributed under the Crea...
Abstract Background Tacrolimus is a widely used calci...
Purpose: Sirolimus (SRL) has been used to replace calcineurin inhibitors (CNI) for various indicatio...
Background. Calcineurin inhibitor-associated nephrotoxicity and other adverse events have prompted e...
Objective: We analyzed the efficacy and safety of an everolimus with reduced-exposure calcineurin in...
BACKGROUND: Benefits of conversion from calcineurin inhibitor (CNI) to mammalian target of rapamycin...
METHODS: Between January 1995 and December 1999, 185 kidney transplants were performed with tacro...
INTRODUCTION: This study examines the efficacy and toxicity of sirolimus used as primary immunosu...
BACKGROUND: Conversion to sirolimus from calcineurin inhibitor- (CNI), azathioprine- (AZA) and mycop...
BACKGROUND: Replacing a calcineurin inhibitor (CNI) with sirolimus (SRL) may preserve kidney graft f...
OBJECTIVE: The aim of this study was to determine whether ethnicity impacts graft outcomes in kid...
Background/Purpose: Information is needed on renal function improvement after late elimination of ca...
INTRODUCTION: Previous studies have suggested that African-American (AA) ethnicity is a risk fact...
Background. Everolimus (EVR) has demonstrated good efficacy after renal transplantation. Racial disp...
BACKGROUND: Calcineurin-inhibitor (CNI)-induced nephrotoxicity frequently complicates transplantatio...
Copyright © 2012 Bertram L. Kasiske et al. This is an open access article distributed under the Crea...
Abstract Background Tacrolimus is a widely used calci...
Purpose: Sirolimus (SRL) has been used to replace calcineurin inhibitors (CNI) for various indicatio...
Background. Calcineurin inhibitor-associated nephrotoxicity and other adverse events have prompted e...
Objective: We analyzed the efficacy and safety of an everolimus with reduced-exposure calcineurin in...
BACKGROUND: Benefits of conversion from calcineurin inhibitor (CNI) to mammalian target of rapamycin...
METHODS: Between January 1995 and December 1999, 185 kidney transplants were performed with tacro...
INTRODUCTION: This study examines the efficacy and toxicity of sirolimus used as primary immunosu...
BACKGROUND: Conversion to sirolimus from calcineurin inhibitor- (CNI), azathioprine- (AZA) and mycop...
BACKGROUND: Replacing a calcineurin inhibitor (CNI) with sirolimus (SRL) may preserve kidney graft f...